Cite
HARVARD Citation
Marmorino, F. et al. (n.d.). O-017FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO. Annals of oncology. p. . [Online].